New YorkPreserves access to affordable drugs
What it does
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed 1st Chamber
- Passed 2nd Chamber
- To Governor
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2026
- Feb 24REFERRED TO HEALTHLatest
- Vote recorded Floor Vote. Result: pass.Upper
- Feb 24DELIVERED TO ASSEMBLY
- Feb 24PASSED SENATEPassed 2nd Chamber
- Feb 11ADVANCED TO THIRD READING
- Feb 102ND REPORT CAL.
- Feb 91ST REPORT CAL.304
- Vote recorded Health Vote. Result: pass.Upper
- Jan 7REFERRED TO HEALTHMinor
- Jan 7RETURNED TO SENATE
- Jan 7DIED IN ASSEMBLY
- Feb 24REFERRED TO HEALTHLatest
- 2025
- May 20REFERRED TO HEALTHMinor
- Vote recorded Floor Vote. Result: pass.Upper
- May 20DELIVERED TO ASSEMBLY
- May 20PASSED SENATEPassed 1st Chamber
- May 1ADVANCED TO THIRD READING
- Apr 302ND REPORT CAL.
- Apr 291ST REPORT CAL.755
- Vote recorded Finance Vote. Result: pass.Upper
- Mar 4REPORTED AND COMMITTED TO FINANCEMinor
- Vote recorded Health Vote. Result: pass.Upper
- Jan 24REFERRED TO HEALTHIntroduced
- May 20REFERRED TO HEALTHMinor